Using EpitoGen Technology, a set of unique and highly sensitive Covid-19 ELISA tests have been developed to differentiate between humoral responses to vaccine and infection with Covid-19. EpitoGen Technology efficiently expresses short epitopes to vastly improve antibody tests and assist with Covid-19 research. With their increased accuracy and detection of COVID-19 variants, these tests are ideal for studying the immune response to both natural infection and vaccination for COVID-19.
Independent research by the National Institute for Biological Standards and Control (NIBSC) have found the EpitoGen Universal kits to be 99% accurate.
The EpitoGen Universal COVID-19 ELISA is designed with maximum sensitivity to both the Omicron and Delta variants, combined with a set of immunodominant epitopes. These epitopes from viral proteins have 45 corresponding circulating mutants. This combination allows for detection of the broadest range of human anti-COVID-19 antibodies. Each test is comprised of an EpitoGen Universal 96 well COVID-19 IgG ELISA plate, diluent, and 44 single tests or 22 duplicate tests per plate. The EpitoGen Universal COVID-19 test has shown 99.5% accuracy and 98.5% specificity in NIBSC assessment.
The EpitoGen Differential COVID-19 ELISA Test allows for differentiation between vaccine induced and infection induced antibody responses, uncovering important information regarding the effectiveness of vaccines. COVID-19 vaccines are based on the spike protein, therefore detection of antibodies with other viral proteins is indicative of a natural infection. The combination of epitopes offers detection of the broadest range of human spike or non-spike COVID-19 antibodies. Each test has 28 single tests or 14 duplicate tests per plate. The EptioGen Differential COVID-19 Test has a range of 95-100% sensitivity and 99% Specificity.
EpitoGen Technology was recently utilized when Vertebrate Antibodies teamed up with the United Nations Academic Impact, University of Aberdeen, and NHS Grampian, to combine ground-breaking epitope display technologies with innovative AI and serology tests to effectively track antibody response to variants without sacrificing accuracy. The new tests can assess the long-term immunity of individuals and whether immunity is vaccine-induced or is just a natural result of previous exposure to the infection – information that is needed in order to help prevent the spread of infection, and assist with public health guidelines and regulations. Read the full article here: https://www.un.org/en/academic-impact/helping-fight-covid-19-pandemic-artificial-intelligence.